
Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



Potential brain death, notify: • LifeGift <sup>4</sup> • ICU Nurse Manager • Hospital Administrator/Nursing Off-Shift Administrator (NOSA)	<ul> <li>EVALUATION (to be performed by Attending Intensivist, Neurologist, or Neurosurgeon</li> <li>Assess for absence of all of the following: <ul> <li>Pupil reaction to light in both eyes</li> <li>Corneal reflexes</li> <li>Ocular movement with head turning (oculocephalic reflex) when no apparent cervical spine injury exists and ocular movements after caloric testing with ice water (oculovestibular reflex)</li> <li>Sucking and rooting reflexes for infants younger than 6 months</li> <li>Oropharyngeal reflex (gag and cough reflex)</li> <li>Facial movement to noxious stimuli at supraorbital nerve, temporomandibular joint</li> <li>Motor response to noxious stimuli in all four limbs</li> </ul> </li> <li>Perform apnea test, unless contraindicated (see Appendix E) <ul> <li>Note: Apnea test should not be performed if:</li> <li>Patient has a comorbid condition that prevents demonstration of spontaneous respiratory effort or</li> <li>Patient would be placed at undue risk to develop cardiac arrest</li> </ul> </li> </ul>	See Page 2 for further testing
--	--	--------------------------------

<sup>1</sup> For Death by Neurological Criteria Checklist, see Appendix A for adults and Appendix B for pediatrics. See Appendix C for Prerequisites for Physiologic Criteria Necessary Prior to Determination of Neurologic Death. <sup>2</sup> See Appendix D for Conditions That May Interfere with the Clinical Diagnosis of Brain Death

<sup>3</sup> The family or any treating physician may request an Ethics consult under the Clinical Ethics Consultation Policy (#CLN0461)

<sup>4</sup> LifeGift should be notified at time of death, or when death is known to be imminent to make an independent assessment of suitability

Page 1 of 10


# MDAnderson Determination of Death by Neurological Criteria

Cancer Center

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## TESTING FOLLOWING EVALUATION



<sup>1</sup>See Appendix D for Conditions That May Interfere with the Clinical Diagnosis of Brain Death


Page 2 of 10

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

FINDINGS





<sup>1</sup> If the practitioner is unwilling to pronounce the patient's death, the Medical Director and/or the appropriate hospital Executive Officer shall be notified. Refer to the Accommodating Closely Held Personal and/or Religious Beliefs Policy (#ADM0260).

<sup>2</sup> See the Care of the Deceased Policy (#CLN1084)

<sup>3</sup> See the Pronouncement of Death by an Advanced Practice Provider Policy (#CLN0509)

<sup>4</sup> LifeGift should be notified at time of death, or when death is known to be imminent to make an independent assessment of suitability

<sup>5</sup> The family or any treating physician may request an Ethics consult under the Clinical Ethics Consultation Policy (#CLN0461)

<sup>6</sup> The time between pronouncement of death and discontinuation of mechanical support should not exceed 6 hours. Under rare circumstances, the time period may be extended by 24-48 hours on a case by case basis, following consultation with Legal services.

**Page 3 of 10** 

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## **APPENDIX A: Death by Neurological Criteria Checklist - Adult**

- □ Pre-Evaluation
- □ **Family Meeting** Attendees/discussed with:
- □ Notify LifeGift of potential Brain Death
- □ Clinical Examination
- □ Apnea Testing
- <u>or</u>
- □ Apnea test aborted Reason:
- □ Ancillary testing (only 1 needs to be performed; to be ordered only if clinical examination cannot be fully performed due to patient factors, or if apnea testing inconclusive or aborted)
- □ Continued Clinical Management
- $\hfill\square$  Pronounce Death in accordance with policy
  - □ Document time in medical record
- □ Notify LifeGift of Death
- □ Planned removal of Mechanical Support
- Organ Donation Procedures through LifeGift
- □ Documentation of all of the above in the Medical Record

Name of physician and signature:

Date & time

Page 4 of 10

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## **APPENDIX B: Death by Neurological Criteria Checklist - Pediatric**

□ Pre-Evaluation	□ Clinical Examination #2
Family Meeting #1     Attendees/discussed with:	<ul> <li>Apnea Testing (Pediatric Considerations)</li> <li><u>or</u></li> <li>Apnea test aborted</li> </ul>
	Reason:
Notify LifeGift of potential Brain Death	Continued Clinical Management
□ Clinical Examination #1	
	Pronounce Death in accordance with policy
Apnea Testing (Pediatric Considerations)	Document time in medical record
Apnea test aborted Reason:	Notify LifeGift of Death
	Planned removal of Mechanical Support
	Organ Donation Procedures through LifeGift
□ Ancillary testing (only 1 needs to be performed; to be ordered only if clinical	Documentation of all of the above in the Medical Record
examination cannot be fully performed due to patient factors, or if apnea testing inconclusive or aborted)	Name of physician and signature: (Exam 2)

□ Documentation of all of the above in the Medical Record

Name of physician and signature: (Exam 1)

Date & time

Page 5 of 10

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **APPENDIX C: Prerequisites for Physiologic Criteria Necessary Prior to Determination of Neurologic Death** All of the following physical criteria must be met: • Central nervous system drug effect absent (if indicated toxicology screen; if barbiturates given, serum level $< 10 \,\mu g/mL$ ) • No evidence of residual paralytics (electrical stimulation if paralytics used) • Absence of severe acid-base, electrolyte, endocrine abnormality • Normothermia or mild hypothermia (core temperature > 36°C) • No spontaneous respirations • Systolic blood pressure (SBP): Adults and children $\geq 10$ years old $SBP \ge 100 \text{ mmHg}$ Children 1-9 years old SBP > [70 + (2 x age in years)] mmHgInfant < 1 year old SBP > 70 mmHgNewborns < 28 days old SBP > 60 mmHgPer American Academy of Neurology (AAN) Guidelines

#### **APPENDIX D: Conditions That May Interfere with the Clinical Diagnosis of Brain Death**

- Severe facial trauma
- Pre-existing pupil abnormalities
- Toxic levels of aminoglycosides, tricyclic antidepressants, anticholinergics, antiepileptic drugs or chemotherapeutic agents
- Anesthetic levels of opiates and sedatives
- Neuromuscular blocking medications
- Sleep apnea or severe pulmonary disease resulting in chronic retention of carbon dioxide
- Therapeutic hypothermia treatment
- Mydriatic medications, psychoactive substances, central nervous system depressants

Page 6 of 10

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## **APPENDIX E: Conducting Apnea Test<sup>1,2</sup>**

#### Step 1:

A. In adults, adjust vasopressors to a systolic blood pressure (SBP)  $\ge 100 \text{ mmHg}$  and mean arterial pressure (MAP)  $\ge 75 \text{ mmHg}$ .

In children, if hemodynamically unstable prior to or during apnea test, adjust vasopressor support to maintain SBP and  $MAP \ge$  fifth percentile for age.

#### Then:

B. Give patient 100% oxygen for at least 10 minutes prior to starting the test. Manage ventilator rate to achieve partial pressure of carbon dioxide (PaCO<sub>2</sub>) 35-45 mmHg. If not achievable, abort apnea test.

#### Step 2:

Obtain baseline arterial blood gases (ABGs)<sup>3</sup> then disconnect the patient from the ventilator<sup>1</sup>.

#### Step 3:

Once disconnected, insert oxygen source into endotracheal tube (ETT) and give patient oxygen at flow rate of 6 L/minute (loose fitting catheter through ETT).

#### **Step 4: Observation/Evaluation**

- A. If patient exhibits any of the following: hypoxia, arrhythmia, or hypotension (SBP persistently < 90 mmHg in adults and children 10 years of age or older despite adjustment of vasopressors; for younger children use Appendix B for blood pressure parameters). Abort test immediately and draw ABG<sup>3</sup>.
- B. If no symptoms as listed in 'A', continue observation for required time period.
- C. Observe adult and pediatric patients carefully for respiratory effort for approximately eight (8) minutes. Draw serial ABG's<sup>3</sup> (approximately every 2 minutes) beginning at approximately 8 minutes of apnea until the ABG results are consistent with the criteria below:

Observations	Evaluation
Unable to complete due to physical condition	$\rightarrow$ Continue with clinically appropriate management
<ul> <li>No respirations or effort occurs and</li> <li>Arterial pH level is &lt; 7.30 and</li> <li>PaCO<sub>2</sub> levels: <ul> <li>In patients who are known not to have chronic carbon dioxide (CO<sub>2</sub>) retention, the PaCO<sub>2</sub> level is ≥ 60 mmHg and ≥ 20 mmHg above the patient's pre-apnea test baseline level</li> <li>In patients who are known to have chronic CO<sub>2</sub> retention, and the baseline PaCO<sub>2</sub> is known, the PaCO<sub>2</sub> level is ≥ 60 mmHg and ≥ 20 mmHg above the patient's known chronic elevated premorbid baseline level</li> <li>In patients who are suspected to have chronic CO<sub>2</sub> retention, but the baseline PaCO<sub>2</sub> is unknown, the PaCO<sub>2</sub> level is ≥ 60 mmHg and ≥ 20 mmHg above the patient's known chronic elevated premorbid baseline level</li> </ul> </li> </ul>	<ul> <li>→ Apnea test is satisfactorily completed and positive (supports the clinical diagnosis of brain death)</li> <li>→ If not, result indeterminate; consider an additional ancillary test</li> <li>→ If result is inconclusive and patient is hemodynamically stable, consider continuing the test for a longer period (11-15 minutes)</li> </ul>

<sup>1</sup>Note: Responsible attending physician (Intensivist, and/or Neurologist/Neurosurgeon) present at the bedside immediately prior to disconnecting the patient from the ventilator and during the apnea test <sup>2</sup>If the apnea test cannot be completed because of hemodynamic instability, desaturation to < 85%, inability to reach a PaCO<sub>2</sub> of > 60 mmHg, or is contraindicated, then an ancillary study should be performed

<sup>3</sup>Point of care testing is recommended

**Page 7 of 10** 

## THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Molina Cancer Histor<sup>®</sup> Molina Cancer Histo THE UNIVERSITY OF TEXAS

Making Cancer History®

determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **APPENDIX F: Minimum Time Duration Between Clinical Exams**

Age	Hours Between Examination
Term newborns (37 weeks gestational age) – 30 days of life	24
Infants 31 days old – children 18 years old	12

Per American Academy of Pediatrics (AAP) Guidelines

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## SUGGESTED READINGS

Aboubakr, M. & Alameda, G. (2020). Brain death criteria. *StatPearls*. Retrieved June 6, 2020, from https://www.ncbi.nlm.nih.gov/books/NBK545144/

- American Academy of Neurology. (2010). Update: Determining brain death in adults (AAN summary of evidence-based guideline for clinicians). Retrieved from https://www.aan.com/Guidelines/home/GetGuidelineContent/432
- American Academy of Pediatrics. (1987). Report of special task force. Guidelines for the determination of brain death in children. *Pediatrics*, 80(2), 298-300. Retrieved from https://pediatrics.aappublications.org/content/pediatrics/80/2/298.full.pdf
- Greer, D. M., Kirschen, M. P., Lewis, A., Gronseth, G. S., Rae-Grant, A., Ashwal, S., . . . Halperin, J. J. (2023). Pediatric and adult brain death/death by neurologic criteria consensus guideline. Report of the AAN Guidelines Subcommittee, AAP, CNS, and SCCM. *Neurology*, 101, 1-21. https://doi.org/10.1212/WNL.000000000207740
- Greer, D. M., Shemie, S. D., Lewis, A., Torrance, S., Varelas, P., Goldenberg, F. D., . . . Sung, G. (2020). Determination of brain death/death by neurologic criteria. The World Brain Death Project. *JAMA*, 324(11), 1078-1097. https://doi.org/10.1001/jama.2020.11586
- Koszer, S. (2018). Determination of brain death in children. Medscape. Retrieved from https://emedicine.medscape.com/article/1177999-overview#showall
- Lewis, A., Bakkar, A., Kreiger-Benson, E., Kumpfbeck, A., Liebman, J., Shemia, S. D., . . . Greer, D. (2020). Determination of death by neurologic criteria around the world. *Neurology*, 95(3), e299-e309. https://doi.org/10.1212/WNL.00000000009888
- Lewis, A., Bernat, J. L., Blosser, S., Bonnie, R. J., Epstein, L. G., Hutchins, J., . . . Greer, D. M. (2018). An interdisciplinary response to contemporary concerns about brain death determination. *Neurology*, *90*(9), 423-426. https://doi.org/10.1212/WNL.00000000005033
- Martin, S. D. & Porter, M. B. (2017). Performing the brain death examination and the declaration of pediatric brain death. *Journal of Pediatric Intensive Care, 6*(4), 229-233. https://doi.org/10.1055/s-0037-1604013
- MD Anderson Institutional Policy # ADM0260 Accommodating Closely Held Personal and/or Religious Beliefs Policy
- MD Anderson Institutional Policy # CLN1084 Care of the Deceased Policy
- MD Anderson Institutional Policy # CLN0461 Clinical Ethics Consultation Policy
- MD Anderson Institutional Policy # CLN0557 Determination of Medical Appropriateness Policy
- MD Anderson Institutional Policy # CLN0509 Pronouncement of Death by an Advanced Practice Provider Policy
- Nakagawa, T. A., Ashwal, S., Mathur, M., Mysore, M. R., Society of Critical Care Medicine, Section on Critical Care and Section on Neurology of the American Academy of Pediatrics, & Child Neurology Society. (2011). Clinical report-guidelines for the determination of brain death in infants and children: An update of the 1987 Task Force recommendations. *Pediatrics, 128*(3), e720-e740. https://doi.org/10.1542/peds.2011-1511
- Wijdicks, E. F. M., Varelas, P. N., Gronseth, G. S., & Greer, D. M. (2010). Evidence-based guideline update: Determining brain death in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology, 74(23), 1911-1918. https://doi.org/10.1212/WNL.0b013e3181e242a8

Page 9 of 10

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## **DEVELOPMENT CREDITS**

This practice consensus statement is based on majority opinion of The Neurologic Death Task Force of the ICU Best Practice Committee Members at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

#### **Core Development Team Leads**

Joshua Botdorf, DO (Critical Care Medicine) John Crommett, MD (Critical Care Medicine) Rodrigo Mejia, MD (Pediatrics - Patient Care) Joseph Nates, MD (Critical Care Medicine) Nico Nortje, PhD, MA, MPhil, HEC-C (Integrated Ethics)

#### Workgroup Members

Wendy Garcia, BS<sup>•</sup> Angela Hayes-Rodgers, MBA/HCM (Off-Shift Administration) Thoa Kazantsev, MSN, RN, OCN<sup>•</sup> Komal Shah, MD (Neuroradiology) John Slopis, MD, MPH (Neuro-Oncology) Jeffrey Weinberg, MD (Neurosurgery) Courtney Wilkes, BSN, RN, CCRN (Nursing ICU)

\* Clinical Effectiveness Development Team

Page 10 of 10